Genmab A/S Share Price Today: Live Updates & Key Insights
Genmab A/S share price today is $25.1, up -2.45%. The stock opened at $25.62 against the previous close of $25.73, with an intraday high of $25.705 and low of $24.96.
Genmab A/S Share Price Chart
Genmab A/S Share Price Performance
Genmab A/S Institutional Holdings
Genmab A/S Market Status
Genmab A/S Fundamentals
Market Cap 15497.58 M
PB Ratio 2.6364
PE Ratio 16.2987
Enterprise Value 19200.69 M
Total Assets 81858.70 M
Volume 2196798
Genmab A/S Company Financials
About Genmab A/S & investment objective
Company Information Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Organisation Biotechnology
Employees 2973
Industry Biotechnology
CEO Dr. Jan G.J. van de Winkel Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Genmab A/S FAQs
What is the share price of Genmab A/S today?
The current share price of Genmab A/S is $25.1.
Can I buy Genmab A/S shares in India?
Yes, Indian investors can buy Genmab A/S shares by opening an international trading and demat account with Motilal Oswal.
How to buy Genmab A/S shares in India?
You can easily invest in Genmab A/S shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Genmab A/S shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Genmab A/S.
Can I buy fractional shares of Genmab A/S?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Genmab A/S?
Genmab A/S has a market cap of $15497.58 M.
In which sector does Genmab A/S belong?
Genmab A/S operates in the Biotechnology sector.
What documents are required to invest in Genmab A/S stocks?
To invest, you typically need:
What is the PE and PB ratio of Genmab A/S?
The PE ratio of Genmab A/S is 16.30 and the PB ratio is 2.64.